Adrenalectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Adrenalectomy is the surgical removal of one or both adrenal glands, performed to treat functional adrenal tumours producing excess hormones, adrenal masses with malignant potential, or adrenocortical carcinoma. The adrenal glands are retroperitoneal endocrine organs sited bilaterally on the superior poles of the kidneys, measuring approximately 4x3x1 cm in each adult. Their proximity to the kidney, inferior vena cava (right adrenal), and aorta (left adrenal), as well as their rich vascular supply from multiple small feeding arteries and a single large adrenal vein, make adrenalectomy a technically demanding procedure requiring specialist endocrine surgical expertise.

Laparoscopic adrenalectomy — either transperitoneal (lateral transabdominal) or retroperitoneoscopic (posterior retroperitoneal) — has been the gold-standard approach since the 1990s for adrenal tumours up to 8-10 cm without imaging features of malignancy. The laparoscopic approach achieves equivalent oncological outcomes to open surgery for benign adrenal tumours with substantially reduced morbidity: shorter hospital stay (2-3 versus 5-7 days), less post-operative pain, faster return to normal activities, lower wound complication rates, and reduced intra-operative blood loss. Posterior retroperitoneoscopic adrenalectomy (PRA) has become increasingly preferred at high-volume centres as it avoids peritoneal access entirely, reducing ileus, intraperitoneal adhesion risk, and operative time in experienced hands.

The pre-operative preparation is critical and varies by tumour type. Phaeochromocytoma resection requires mandatory alpha-adrenergic blockade for 10-14 days before surgery to prevent intraoperative hypertensive crisis. Cushing's syndrome patients require post-operative glucocorticoid cover and gradual replacement tapering. Primary hyperaldosteronism patients may require potassium normalisation before surgery. This physiological complexity demands that adrenalectomy be performed by surgical teams with specialist endocrine surgery training working in close collaboration with experienced endocrinologists and anaesthesiologists.

For international patients, adrenalectomy at specialist endocrine surgery departments in India, Thailand, and Germany offers equivalent outcomes to Western centres at substantially reduced cost, with India in particular having a strong tradition of endocrine surgery excellence at major academic hospitals.

Phaeochromocytoma — a catecholamine-secreting chromaffin cell tumour arising from the adrenal medulla — is a compelling surgical indication. Untreated phaeochromocytoma carries risk of life-threatening hypertensive crises, cardiac arrhythmias, and stroke. Complete surgical resection is curative in over 95% of benign sporadic cases, with laparoscopic approach preferred for tumours up to 8 cm. Bilateral phaeochromocytoma (occurring in hereditary syndromes such as MEN2, VHL, or SDH gene mutations) may require cortical-sparing adrenalectomy to preserve cortical function and avoid permanent adrenal insufficiency.

Primary hyperaldosteronism (Conn's syndrome) from a unilateral aldosterone-producing adenoma is treated by laparoscopic adrenalectomy, achieving blood pressure normalisation without medication in 40-70% of patients and potassium normalisation in over 95%. Adrenocortical adenoma causing Cushing's syndrome (ACTH-independent adrenal Cushing's) is treated by unilateral laparoscopic adrenalectomy with over 95% cure rate. Adrenocortical carcinoma — a rare but aggressive malignancy — requires open radical adrenalectomy with en-bloc resection of adjacent involved structures, often followed by adjuvant mitotane chemotherapy. Adrenal incidentalomas above 4 cm in size, or those with CT attenuation above 10 Hounsfield units suggesting lipid-poor (potentially malignant) composition, require resection for oncological safety.

Candidates for adrenalectomy include patients with confirmed functional adrenal tumours causing hormonal excess (phaeochromocytoma, aldosteronoma, cortisol-producing adenoma), adrenal masses meeting size criteria or radiological features suggesting malignancy, and adrenocortical carcinoma requiring surgical resection as the primary treatment. Pre-operative biochemical confirmation of hormonal activity is mandatory for all patients considered for adrenalectomy, as non-functioning adrenal incidentalomas below 4 cm can be managed with surveillance.

Fitness for surgery is assessed with full pre-operative cardiorespiratory evaluation. Laparoscopic approach is contraindicated for tumours with CT imaging features of malignancy (irregular borders, heterogeneous enhancement, surrounding tissue invasion) where open surgery with adequate oncological margins is required. Prior ipsilateral adrenal surgery, known extensive intraperitoneal adhesions, and morbid obesity (BMI above 40) may favour open surgery in individual cases. Coagulopathy must be corrected before surgery given the risk of haemorrhage from adrenal vascular anatomy.

Laparoscopic lateral transabdominal adrenalectomy (LLTA) is performed with the patient in a lateral decubitus position using 3-4 laparoscopic ports. The right adrenal is accessed by mobilising the liver and the right hepatic flexure of the colon; the left adrenal is accessed by mobilising the spleen and tail of pancreas. The adrenal vein is identified and clipped early during the dissection — on the right, it is a short vessel draining directly into the inferior vena cava; on the left, it drains into the left renal vein. Complete gland mobilisation from surrounding fat is then performed using an energy device (LigaSure or Harmonic scalpel).

Posterior retroperitoneoscopic adrenalectomy (PRA) places the patient prone on a Montreal mattress and accesses the adrenal through 3 trocar ports in the retroperitoneum, blunt balloon dissection creating a working space between Gerota's fascia and the posterior abdominal wall musculature. PRA provides direct and rapid access to the adrenal gland without entering the peritoneal cavity, making it the preferred approach at most high-volume endocrine surgery centres for bilateral synchronous adrenalectomy and for patients with prior abdominal surgeries. Robotic-assisted laparoscopic adrenalectomy offers enhanced 3D visualisation and wristed instrument articulation, particularly valuable for right adrenalectomy where the short adrenal vein demands precise dissection near the IVC. Open adrenalectomy via flank, midline, or subcostal incision is used for large tumours (above 8-10 cm), suspected adrenocortical carcinoma, or when laparoscopic approach is contraindicated.

Laparoscopic adrenalectomy achieves clinical and biochemical cure in the vast majority of benign adrenal tumours. For Conn's syndrome from aldosteronoma, complete cure of hypertension (off all antihypertensive medications) occurs in 40-70% at 6 months, with significant blood pressure improvement in an additional 25%. Younger patients, those with shorter duration of hypertension, and those without established end-organ damage have the best blood pressure outcomes. Hypokalaemia resolves in over 95% of cases.

For phaeochromocytoma, biochemical cure — defined as normalisation of plasma or urine metanephrines within 4-6 weeks post-operatively — is achieved in over 95% of benign sporadic tumours. Hypertensive crises and cardiovascular risk normalise within months of surgical cure. For adrenal Cushing's syndrome, unilateral adrenalectomy achieves complete biochemical remission in over 95% of benign adenoma cases, with gradual clinical improvement — resolution of truncal obesity, hypertension, diabetes, and osteoporosis risk — over 12-24 months as the hypothalamic-pituitary-adrenal axis recovers normal function.

Haemorrhage is the most significant intraoperative risk, arising from the adrenal vein or feeding arteries. The right adrenal vein's short course draining directly into the IVC makes right adrenalectomy technically more demanding than left. Conversion to open surgery due to haemorrhage occurs in 1-3% of laparoscopic procedures. Injury to adjacent structures — spleen (left adrenalectomy, 0.5%), liver (right adrenalectomy, 0.3%), kidney (0.2%), and bowel — occurs at low but non-zero rates, emphasising the importance of surgical experience.

Phaeochromocytoma resection specifically carries risk of intraoperative hypertensive crisis (5-15% even with adequate alpha-blockade) from catecholamine release during gland handling before venous occlusion, and post-operative hypotension from abrupt catecholamine withdrawal after adrenal vein ligation — both managed by experienced anaesthesia teams. Post-operative adrenal insufficiency requires mandatory cortisol replacement in patients having bilateral adrenalectomy (permanent) or in those with contralateral adrenal suppression from longstanding cortisol excess (temporary, tapering over 6-18 months). Adrenal crisis from cortisol deficiency in the perioperative period can be life-threatening if not anticipated and managed with adequate steroid cover.

Laparoscopic adrenalectomy patients are typically discharged 2-3 days post-operatively. Oral analgesics (paracetamol, NSAIDs) manage post-operative pain. Return to driving at 2-3 weeks and light office work at 2-3 weeks, with full physical recovery by 4-6 weeks. Open adrenalectomy patients require 5-7 days hospitalisation and 6-8 weeks for full recovery.

Biochemical follow-up depends on tumour type. For phaeochromocytoma: plasma metanephrines and normetanephrines at 4-6 weeks, 6 months, and annually thereafter to detect recurrence — lifelong surveillance is recommended, with more intensive surveillance for hereditary cases. For Conn's syndrome: aldosterone-renin ratio and blood pressure review at 1 and 3 months. For adrenal Cushing's syndrome: morning serum cortisol to guide hydrocortisone weaning; ACTH stimulation test at 6 and 12 months to document HPA axis recovery. For adrenocortical carcinoma: CT chest/abdomen at 3-monthly intervals for 2 years, with mitotane level monitoring.

Laparoscopic adrenalectomy in the United States costs $20,000-$40,000 including hospital, surgeon, and anaesthesia fees. For complex phaeochromocytoma with intensive care and prolonged monitoring, total costs may reach $60,000-$80,000. In the United Kingdom under private care, laparoscopic adrenalectomy costs £12,000-£20,000. Open adrenalectomy for adrenocortical carcinoma at a US oncology centre may exceed $100,000 for the surgical episode alone.

At leading endocrine surgery centres in India — Apollo Hospitals Delhi, Medanta Gurugram, AIIMS Delhi, Kokilaben Dhirubhai Ambani Hospital — laparoscopic adrenalectomy costs $5,000-$10,000 all-inclusive. Bangkok (Bumrungrad International Hospital) charges $8,000-$15,000. Germany's high-volume endocrine surgery centres charge €10,000-€20,000. Patients save 50-70% on planned adrenalectomy costs at accredited international centres. For phaeochromocytoma specifically, comprehensive pre-operative alpha-blockade and anaesthetic preparation must be coordinated with the treating endocrine team regardless of surgical location.

Radiofrequency ablation (RFA) and microwave ablation of adrenal masses are emerging minimally invasive alternatives for patients who are surgically unfit or who decline surgery, particularly for small adrenal metastases or small functional tumours in high-risk individuals. These techniques achieve local tumour control in 70-85% of cases for lesions under 3 cm, though they are not yet considered standard of care for primary functional adrenal tumours where surgery achieves near-universal cure.

For primary hyperaldosteronism from bilateral adrenal hyperplasia — where unilateral adrenalectomy would not be curative — long-term mineralocorticoid receptor antagonist therapy (spironolactone 25-100 mg/day or eplerenone 50-200 mg/day) achieves blood pressure control and potassium normalisation without surgery. For adrenocortical carcinoma and metastatic disease, mitotane (adrenolytic agent) combined with cytotoxic chemotherapy (EDP: etoposide, doxorubicin, cisplatin) provides palliative control but rarely achieves remission. For malignant phaeochromocytoma, MIBG (meta-iodobenzylguanidine) radionuclide therapy and systemic tyrosine kinase inhibitors (sunitinib) offer palliative options.